Biotechnology
Azenta Q4 Revenue Rises 5% as Sample Management Solutions Grows 9%
Add Securities.io to your preferred sources on Google
Azenta’s fourth-quarter and full-year results, published November 10, 2026, showed revenue from continuing operations rising 5% year over year to $167.1 million for the quarter ended September 30, 2026. Adjusted EBITDA, a company-defined profitability measure, fell 7% to $19.4 million, and its margin narrowed 140 basis points to 11.6%.
Sample Management Solutions revenue grew 9% to $94 million, while Multiomics revenue was flat at $73 million. Total organic revenue growth was 2%, excluding a nominal foreign-exchange effect and a 3-percentage-point contribution from the UK Biocentre acquisition. Higher Sample Repository Services and Consumables and Instruments revenue was partly offset by lower Automated Stores revenue. Within Multiomics, Gene Synthesis growth partly offset lower Sanger Sequencing and Next Generation Sequencing revenue.
Azenta’s supplemental earnings information reported low-teens Gene Synthesis growth, aided by particularly strong demand in China, against a high-teens decline in Sanger sequencing and a low-single-digit decline in Next Generation Sequencing.
Annual Loss Reflects Goodwill Impairment
For fiscal 2026, continuing operations produced a $157.9 million net loss despite 5% revenue growth. The result included a $149.1 million non-cash goodwill impairment recognized in the second quarter, comprising $112.4 million for Multiomics and $36.6 million for Sample Management Solutions.
Fiscal 2026 free cash flow was $27 million on a total-company basis, using Azenta’s definition of operating cash flow less capital expenditures.
New Investments Shape Fiscal 2027
On October 28, 2026, Azenta entered licensing, equipment, supply and service agreements with Elegen. Azenta expects aggregate capital deployment under the agreements of approximately $32 million to $71 million, depending on future equipment purchases and whether it exercises an option to convert the license into a perpetual exclusive license.
It also acquired DNA-assembly company SynPlexity that day for a $15 million cash base price, plus up to $10 million of contingent consideration tied to a revenue milestone through September 30, 2029. Both transactions expand Multiomics’ gene-synthesis capabilities.
Management’s fiscal 2027 outlook calls for reported revenue from continuing operations of approximately $648 million to $660 million and organic growth of 3% to 5%. Sample Management Solutions is expected to grow organically at a mid-single-digit rate and Multiomics at a low-single-digit rate. The high end of the range includes potential contributions from Elegen and SynPlexity, with fiscal 2027 expected to focus primarily on integration, scale-up and commercialization.
The outlook also targets 200 to 250 basis points of adjusted EBITDA margin expansion, inclusive of approximately 100 basis points of expected dilution from the transactions. Free cash flow is expected to improve approximately 25% from fiscal 2026.
The investments give Azenta additional gene-synthesis technology, but they also tie the outlook to successful integration and commercialization. The open question is whether those efforts can produce sustained Multiomics growth while Azenta absorbs the expected dilution and delivers the targeted margin and cash-flow improvement.
